PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27190598-6	2016	Generation of a library of molecules resulted in the identification of the most selective inhibitor of SphK1 reported to date (705-fold selectivity over SphK2), and we found that potency and selectivity vary significantly depending on the particular oxadiazole isomer employed.	Oxadiazoles	250-260	sphingosine kinase 1	Homo sapiens	103-108
27149363-3	2016	Current study explores the alpha-glucosidase inhibition of a hybrid class of compounds of oxadiazole and benzofurans.	Oxadiazoles	90-100	sucrase-isomaltase	Homo sapiens	27-44
26845138-6	2016	To circumvent this problem, a lot of scientists in the world synthesized a series of cis-restricted CA-4 analogs, where the double bond has been replaced by introduction of non-heterocyclic groups or heterocyclic groups like beta -lactam and oxadiazole.	Oxadiazoles	242-252	carbonic anhydrase 4	Homo sapiens	100-104
26183542-0	2015	Synthesis of new oxadiazole derivatives as alpha-glucosidase inhibitors.	Oxadiazoles	17-27	sucrase-isomaltase	Homo sapiens	43-60
26526743-0	2015	Synthesis of novel benzohydrazone-oxadiazole hybrids as beta-glucuronidase inhibitors and molecular modeling studies.	Oxadiazoles	34-44	glucuronidase beta	Homo sapiens	56-74
26178333-0	2015	Prospective QSAR-Based Prediction Models with Pharmacophore Studies of Oxadiazole-Substituted alpha-Isopropoxy Phenylpropanoic Acids with Dual Activators of PPARalpha and PPARgamma.	Oxadiazoles	71-81	peroxisome proliferator activated receptor alpha	Homo sapiens	157-166
26178333-0	2015	Prospective QSAR-Based Prediction Models with Pharmacophore Studies of Oxadiazole-Substituted alpha-Isopropoxy Phenylpropanoic Acids with Dual Activators of PPARalpha and PPARgamma.	Oxadiazoles	71-81	peroxisome proliferator activated receptor gamma	Homo sapiens	171-180
26178333-1	2015	A series of oxadiazole-substituted [Formula: see text]-isopropoxy phenylpropanoic acids with dual activators of PPARalpha and PPARgamma derivatives were subjected to two-dimensional and k-Nearest Neighbors molecular field analysis.	Oxadiazoles	12-22	peroxisome proliferator activated receptor alpha	Homo sapiens	112-121
26178333-1	2015	A series of oxadiazole-substituted [Formula: see text]-isopropoxy phenylpropanoic acids with dual activators of PPARalpha and PPARgamma derivatives were subjected to two-dimensional and k-Nearest Neighbors molecular field analysis.	Oxadiazoles	12-22	peroxisome proliferator activated receptor gamma	Homo sapiens	126-135
26726422-1	2015	Novel thermally activated delayed fluorescence (TADF) materials (ACR-OXD, 2ACR-OXD) with 9,10-dihydro-9,9-dimethylacridine (ACR) as an electron donor and oxadiazole derivative (OXD) as an electron acceptor were designed and theoretically investigated for blue OLED emitter.	Oxadiazoles	154-164	acrosin	Homo sapiens	65-68
26148672-0	2015	Quantitative and qualitative analysis of the novel antitumor 1,3,4-oxadiazole derivative (GLB) and its metabolites using HPLC-UV and UPLC-QTOF-MS. Fructose-based 3-acetyl-2,3-dihydro-1,3,4-oxadiazole (GLB) is a novel antitumor agent and belongs to glycosylated spiro-heterocyclic oxadiazole scaffold derivative.	Oxadiazoles	67-77	dicarbonyl and L-xylulose reductase	Rattus norvegicus	90-93
25643074-6	2015	Surprisingly, homologation with a single methylene unit between the oxadiazole and heterocyclic ring afforded a SphK1-selective inhibitor in SLP7111228 (Ki = 48 nM), which also decreased S1P levels in cultured U937 cells.	Oxadiazoles	68-78	sphingosine kinase 1	Homo sapiens	112-117
25643074-4	2015	Herein, we report the design, synthesis, and structure-activity relationship studies of guanidine-based SphK inhibitors bearing an oxadiazole ring in the scaffold.	Oxadiazoles	131-141	sphingosine kinase 1	Homo sapiens	104-108
25671290-0	2015	Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).	Oxadiazoles	46-56	arachidonate 5-lipoxygenase	Homo sapiens	68-82
25671290-1	2015	The synthesis, structure-activity relationship (SAR), and evolution of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are described.	Oxadiazoles	89-99	arachidonate 5-lipoxygenase	Homo sapiens	111-125
25452003-0	2014	DeltaF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.	Oxadiazoles	97-108	CF transmembrane conductance regulator	Homo sapiens	10-14
25255433-0	2014	Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-gamma agonists.	Oxadiazoles	82-92	peroxisome proliferator activated receptor gamma	Homo sapiens	143-153
25303727-0	2014	Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.	Oxadiazoles	59-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	83-88
23143678-3	2013	We have recently realized a series of new inhibitors based on the 4-hydroxy-1,2,5-oxadiazole ring, whose activity profile was found to be closely dependent on the degree of fluorine substitution at the phenyl ring adjacent to the oxadiazole moiety; a positive influence of fluorine on the DHODH inhibitory potency was observed previously [Baumgartner et al.	Oxadiazoles	82-92	dihydroorotate dehydrogenase (quinone)	Homo sapiens	289-294
25151088-0	2014	Oxadiazoles and thiadiazoles: novel alpha-glucosidase inhibitors.	Oxadiazoles	0-11	sucrase-isomaltase	Homo sapiens	36-53
25151088-1	2014	Oxadiazoles and thiadiazoles 1-37 were synthesized and evaluated for the first time for their alpha-glucosidase inhibitory activities.	Oxadiazoles	0-11	sucrase-isomaltase	Homo sapiens	94-111
24081608-1	2014	The binding modes of 42 oxadiazole derivates inside glycogen synthase kinase 3 beta (GSK3beta were determined using docking experiments; thus, the preferred active conformations of these inhibitors are proposed.	Oxadiazoles	24-34	glycogen synthase kinase 3 beta	Homo sapiens	52-83
24081608-1	2014	The binding modes of 42 oxadiazole derivates inside glycogen synthase kinase 3 beta (GSK3beta were determined using docking experiments; thus, the preferred active conformations of these inhibitors are proposed.	Oxadiazoles	24-34	glycogen synthase kinase 3 beta	Homo sapiens	85-93
24072592-4	2013	We show that the resulting oxadiazole-substituted aza-benzimidazole is a potent and ligand efficient S6 kinase inhibitor, which blocks the phosphorylation of RPS6 at Ser235/236 in TSC negative HCV29 human bladder cancer cells by inhibiting S6 kinase activity and thus provides a useful tool compound to investigate the function of S6 kinases.	Oxadiazoles	27-37	ribosomal protein S6	Homo sapiens	158-162
22749643-0	2013	Structure-based optimization of oxadiazole-based GSK-3 inhibitors.	Oxadiazoles	32-42	glycogen synthase kinase 3 beta, genome duplicate a	Danio rerio	49-54
22749643-4	2013	Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors.	Oxadiazoles	18-28	glycogen synthase kinase 3 beta, genome duplicate a	Danio rerio	68-73
25183350-0	2014	Prospective QSAR-based prediction models with pharmacophore studies of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids on with dual activators of PPARalpha and PPARgamma A series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with dual activators of PPARalpha and PPARgamma derivatives were subjected to two dimensional and k-nearest neighbour Molecular field analysis.	Oxadiazoles	71-81	peroxisome proliferator activated receptor alpha	Homo sapiens	160-169
25183350-0	2014	Prospective QSAR-based prediction models with pharmacophore studies of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids on with dual activators of PPARalpha and PPARgamma A series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with dual activators of PPARalpha and PPARgamma derivatives were subjected to two dimensional and k-nearest neighbour Molecular field analysis.	Oxadiazoles	71-81	peroxisome proliferator activated receptor gamma	Homo sapiens	174-183
24979042-1	2014	We present here a simple, milder, and environmentally benign heterogeneous catalytic method for the transformation of tetrazines to oxadiazole derivatives at room temperature (25  C) using our earlier synthesized iron-squarate based 3D metal organic framework, [Fe3(OH)3(C4O4)(C4O4)0.5]n (FeSq-MOF).	Oxadiazoles	132-142	lysine acetyltransferase 8	Homo sapiens	294-297
24081608-0	2014	Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3beta.	Oxadiazoles	60-70	glycogen synthase kinase 3 beta	Homo sapiens	98-106
24138603-3	2013	We show that the presence of CsF/Al at cathodes not only improves electron transport in oxadiazole-containing electron transport layers (ETLs), but also facilitates electron injection through the reacted oxadiazole moiety to reduce interface resistance, which results in the enhancement of current efficiency.	Oxadiazoles	88-98	colony stimulating factor 2	Homo sapiens	29-32
24138603-3	2013	We show that the presence of CsF/Al at cathodes not only improves electron transport in oxadiazole-containing electron transport layers (ETLs), but also facilitates electron injection through the reacted oxadiazole moiety to reduce interface resistance, which results in the enhancement of current efficiency.	Oxadiazoles	204-214	colony stimulating factor 2	Homo sapiens	29-32
23504218-1	2013	An oxadiazole derivative(OXD) containing symmetrical pyridine-2-formamidophenyl-binded moiety was synthesised as fluorescence turn-on sensor OA1.	Oxadiazoles	3-13	OA1	Homo sapiens	141-144
23469385-7	2010	The first oxadiazole-based probe (ML236, PubChem CID665654) is potent (35 nM) in a B-cell line and >400-fold selective over both the NF-kappaB activation in T-cells and against TNFalpha-mediated NF-kappaB activation.	Oxadiazoles	10-20	tumor necrosis factor	Homo sapiens	180-188
22608962-0	2012	Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.	Oxadiazoles	55-65	diacylglycerol O-acyltransferase 1	Homo sapiens	66-72
22683241-0	2012	Synthesis and biological evaluation of isoxazole, oxazole, and oxadiazole containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.	Oxadiazoles	63-73	diacylglycerol O-acyltransferase 1	Mus musculus	123-128
21621412-5	2011	Docking studies of triazole-linked reduced amide isostere A3Z10 and potent oxadiazole-linked tertiary carbinamine 2a with BACE1 suggests that the docking poses of A3Z10 and 2a in the active sites are quite similar, with one exception.	Oxadiazoles	75-85	beta-secretase 1	Homo sapiens	122-127
21824692-1	2011	In this study novel ligands of the translocator protein (TSPO), characterized by a five-membered aromatic heterocycle (i.e. oxazole, isoxazole, oxadiazole), a phenyl ring, and an amide side chain of carboxy or acetic type, were designed using a previously reported pharmacophore/topological model.	Oxadiazoles	144-154	translocator protein	Homo sapiens	35-55
21824692-1	2011	In this study novel ligands of the translocator protein (TSPO), characterized by a five-membered aromatic heterocycle (i.e. oxazole, isoxazole, oxadiazole), a phenyl ring, and an amide side chain of carboxy or acetic type, were designed using a previously reported pharmacophore/topological model.	Oxadiazoles	144-154	translocator protein	Homo sapiens	57-61
21316962-2	2011	The oral bioavailability of these compounds could be dramatically improved by optimization studies of the side chains attached to the indole and oxadiazole cores, leading to identification of a CB1 receptor agonist with good oral activity in a range of preclinical models of antinociception and antihyperalgesia.	Oxadiazoles	145-155	cannabinoid receptor 1	Homo sapiens	194-197
20727744-1	2010	With a small series of compounds we demonstrated the variability in the core region of the human histamine H(3) receptor (hH(3)R) antagonist structural blueprint by introducing polar azole groups (oxazole, oxadiazole, thiazole and triazole).	Oxadiazoles	206-216	histamine receptor H3	Homo sapiens	97-120
20965619-7	2010	We had noticed that compounds (AB13, AB20) bearing OH group at one of the phenyl ring of oxadiazole exhibited good antimicrobial properties and their drug-likeness model score were also predicted maximum among the series.	Oxadiazoles	89-99	NBPF member 1	Homo sapiens	31-35
20727744-1	2010	With a small series of compounds we demonstrated the variability in the core region of the human histamine H(3) receptor (hH(3)R) antagonist structural blueprint by introducing polar azole groups (oxazole, oxadiazole, thiazole and triazole).	Oxadiazoles	206-216	histamine receptor H3	Homo sapiens	122-128
20055416-4	2010	Our data revealed that those EA oxadiazole analogues had improved antiproliferative activity and most of them had similar or better inhibitory effects on GST P1-1 activity than EA.	Oxadiazoles	32-42	glutathione S-transferase pi 1	Homo sapiens	154-162
20055416-7	2010	Our data suggest that these EA oxadiazole analogues are promising antitumor agents that may act through GST P1-1 inhibition-dependent and/or -independent pathways.	Oxadiazoles	31-41	glutathione S-transferase pi 1	Homo sapiens	104-112
19197923-2	2009	This effort identified key substituents in the 3-position of oxadiazole that engendered either mGluR5 ago-potentiation or pure mGluR5 positive allosteric modulation.	Oxadiazoles	61-71	glutamate receptor, ionotropic, kainate 1	Mus musculus	95-101
20036129-0	2010	Synthesis and biological evaluation of oxadiazole derivatives as inhibitors of soluble guanylyl cyclase.	Oxadiazoles	39-49	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	79-103
19637873-3	2009	Detailed investigation of the SAR series subsequently revealed that many members of the oxadiazole class (and surprisingly also 1) act via divergent modes of inhibition (competitive or via colloidal aggregation) depending on the assay conditions employed.	Oxadiazoles	88-98	sarcosine dehydrogenase	Homo sapiens	30-33
19370348-15	2009	We postulate that diminished HIF-1alpha nuclear presence in oxadiazole treated EAT cells could be responsible for decreased VEGF expression and antiangiogenic effects.	Oxadiazoles	60-70	hypoxia inducible factor 1, alpha subunit	Mus musculus	29-39
19370348-15	2009	We postulate that diminished HIF-1alpha nuclear presence in oxadiazole treated EAT cells could be responsible for decreased VEGF expression and antiangiogenic effects.	Oxadiazoles	60-70	vascular endothelial growth factor A	Mus musculus	124-128
19637873-2	2009	Chemical optimization of 1 led to a series of oxadiazoles possessing interpretable SAR and potencies as much as 500-fold greater than 1.	Oxadiazoles	46-57	sarcosine dehydrogenase	Homo sapiens	83-86
19197923-2	2009	This effort identified key substituents in the 3-position of oxadiazole that engendered either mGluR5 ago-potentiation or pure mGluR5 positive allosteric modulation.	Oxadiazoles	61-71	glutamate receptor, ionotropic, kainate 1	Mus musculus	127-133
17723300-0	2007	Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.	Oxadiazoles	29-40	beta-1,3-glucuronyltransferase 1	Homo sapiens	51-55
18642893-0	2008	Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors.	Oxadiazoles	0-10	sirtuin 1	Homo sapiens	37-42
18642893-0	2008	Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors.	Oxadiazoles	0-10	sirtuin 2	Homo sapiens	47-52
19802367-2	2009	These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and anti-schistosomal activity.	Oxadiazoles	94-104	thioredoxin reductase 3	Homo sapiens	133-166
19802367-2	2009	These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and anti-schistosomal activity.	Oxadiazoles	94-104	thioredoxin reductase 3	Homo sapiens	168-171
19200745-2	2009	Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3beta inhibitors.	Oxadiazoles	91-101	glycogen synthase kinase 3 beta	Homo sapiens	117-126
19147366-7	2009	Finally, substitution of oxadiazoles for the furan ring abolished affinity for the KOPR.	Oxadiazoles	25-36	opioid receptor kappa 1	Homo sapiens	83-87
19200038-0	2009	Interaction models of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids against PPARalpha and PPARgamma: molecular modeling and comparative molecular similarity indices analysis studies.	Oxadiazoles	34-44	peroxisome proliferator activated receptor alpha	Homo sapiens	104-113
19200038-0	2009	Interaction models of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids against PPARalpha and PPARgamma: molecular modeling and comparative molecular similarity indices analysis studies.	Oxadiazoles	34-44	peroxisome proliferator activated receptor gamma	Homo sapiens	118-127
19200038-1	2009	Molecular recognition of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids by PPARalpha and PPARgamma was investigated by using molecular modeling and 3D-QSAR analyses.	Oxadiazoles	37-47	peroxisome proliferator activated receptor alpha	Homo sapiens	102-111
19200038-1	2009	Molecular recognition of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids by PPARalpha and PPARgamma was investigated by using molecular modeling and 3D-QSAR analyses.	Oxadiazoles	37-47	peroxisome proliferator activated receptor gamma	Homo sapiens	116-125
19200038-5	2009	The oxadiazole-ring-related hydrogen bond interactions well elucidate the structural features governing the different binding behavior of these agonists against PPARalpha and PPARgamma.	Oxadiazoles	4-14	peroxisome proliferator activated receptor alpha	Homo sapiens	161-170
19200038-5	2009	The oxadiazole-ring-related hydrogen bond interactions well elucidate the structural features governing the different binding behavior of these agonists against PPARalpha and PPARgamma.	Oxadiazoles	4-14	peroxisome proliferator activated receptor gamma	Homo sapiens	175-184
19053260-0	2008	Molecular design of new inhibitors of peroxidase activity of cytochrome c/cardiolipin complexes: fluorescent oxadiazole-derivatized cardiolipin.	Oxadiazoles	109-119	cytochrome c, somatic	Homo sapiens	61-73
18951019-4	2008	An oxadiazole moiety behaves as a bioisostere for the hydroxamate group, leading to a more metabolically stable and efficacious MEK inhibitor.	Oxadiazoles	3-13	mitogen-activated protein kinase kinase 7	Homo sapiens	128-131
18680277-2	2008	Herein we describe the discovery of a novel class of oxadiazole derivatives from which potent and selective CB2 agonist leads were developed.	Oxadiazoles	53-63	cannabinoid receptor 2	Rattus norvegicus	108-111
17723300-3	2007	Oxadiazole analog 22 was determined to have excellent hNK(1) binding affinity, functional activity, and a good PD response in vivo.	Oxadiazoles	0-10	beta-1,3-glucuronyltransferase 1	Homo sapiens	54-59
16919457-0	2006	Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.	Oxadiazoles	56-66	dipeptidyl peptidase 4	Homo sapiens	73-96
17574410-1	2007	A novel series of oxadiazole EP1 receptor antagonists was identified by replacing the amide of a known glycine sulfonamide derivative with a 1,3,4-oxadiazole.	Oxadiazoles	18-28	prostaglandin E receptor 1	Homo sapiens	29-32
16919457-1	2006	A novel series of oxadiazole based amides have been shown to be potent DPP-4 inhibitors.	Oxadiazoles	18-28	dipeptidyl peptidase 4	Homo sapiens	71-76
11527737-0	2001	Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta.	Oxadiazoles	30-40	peroxisome proliferator activated receptor alpha	Homo sapiens	109-118
16602792-1	2006	One nanosized oxadiazole bridging ligand, bis(3-acetylenylphenyl-(4-cyanophenyl))oxadiazole (L11), was designed and synthesized by the reaction of bis(3-iodophenyl)oxadiazole with 4-cyanophenylacetylene via a Sonogashira-Hagihara cross-coupling reaction.	Oxadiazoles	14-24	immunoglobulin kappa variable 1-6	Homo sapiens	93-96
16602792-5	2006	In this Ag(I)-L11 system, the conformation of L11 is versatile because of the conformational rotation around the central oxadiazole moiety and depends greatly on the counterion and solvent system used in the formation of the complexes.	Oxadiazoles	121-131	immunoglobulin kappa variable 1-6	Homo sapiens	14-17
16602792-5	2006	In this Ag(I)-L11 system, the conformation of L11 is versatile because of the conformational rotation around the central oxadiazole moiety and depends greatly on the counterion and solvent system used in the formation of the complexes.	Oxadiazoles	121-131	immunoglobulin kappa variable 1-6	Homo sapiens	46-49
16162010-5	2005	The diacylhydrazine was found to be superior over the oxadiazole as an amide bond replacement in the Plm I and II inhibitors studied.	Oxadiazoles	54-64	FXYD domain containing ion transport regulator 1	Homo sapiens	101-104
11527737-0	2001	Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta.	Oxadiazoles	30-40	peroxisome proliferator activated receptor gamma	Homo sapiens	120-129
11527737-0	2001	Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta.	Oxadiazoles	30-40	peroxisome proliferator activated receptor delta	Homo sapiens	135-144
11514143-3	2001	The synthesized oxadiazoles were evaluated for their affinity to the DAT and their ability to inhibit monoamine reuptake at the DAT, NET, and 5HTT.	Oxadiazoles	16-27	solute carrier family 6 member 3	Homo sapiens	69-72
11514143-3	2001	The synthesized oxadiazoles were evaluated for their affinity to the DAT and their ability to inhibit monoamine reuptake at the DAT, NET, and 5HTT.	Oxadiazoles	16-27	solute carrier family 6 member 3	Homo sapiens	128-131
11514143-4	2001	The results show that affinity to the DAT and ability to inhibit the reuptake at the DAT, NET, and 5HTT is a function of the size of the substituent in the oxadiazole ring.	Oxadiazoles	156-166	solute carrier family 6 member 3	Homo sapiens	38-41
11514143-4	2001	The results show that affinity to the DAT and ability to inhibit the reuptake at the DAT, NET, and 5HTT is a function of the size of the substituent in the oxadiazole ring.	Oxadiazoles	156-166	solute carrier family 6 member 3	Homo sapiens	85-88
10395735-6	1999	Nonpeptidic HNE inhibitors containing the oxadiazole heterocycle displayed promising oral bioavailability.	Oxadiazoles	42-52	elastase, neutrophil expressed	Homo sapiens	12-15
8496922-2	1993	Modifications of the oxadiazole 3-substituent, length of the linking chain (n), and the amine substituents are explored and reveal a large binding pocket in the 5-HT1D receptor domain.	Oxadiazoles	21-31	5-hydroxytryptamine receptor 1D	Homo sapiens	161-167
34426156-0	2021	Novel 1,3,4-thiadiazole/oxadiazole-linked honokiol derivatives suppress cancer via inducing PI3K/Akt/mTOR-dependent autophagy.	Oxadiazoles	24-34	AKT serine/threonine kinase 1	Homo sapiens	97-100
18802648-1	2008	A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists.	Oxadiazoles	18-29	cannabinoid receptor 1	Homo sapiens	33-36
18802648-2	2008	Based on the bioisosteric replacement of the pyrazole C3-carboxamide of rimonabant with a 5-alkyl oxadiazole ring, a novel class of oxadiazole derivatives with promising biological activity towards CB1 receptors was discovered.	Oxadiazoles	98-108	cannabinoid receptor 1	Homo sapiens	198-201
34426156-0	2021	Novel 1,3,4-thiadiazole/oxadiazole-linked honokiol derivatives suppress cancer via inducing PI3K/Akt/mTOR-dependent autophagy.	Oxadiazoles	24-34	mechanistic target of rapamycin kinase	Homo sapiens	101-105
34424718-1	2021	It has been reported that DIC can react with OxymaPure to render an oxadiazole compound with the concomitant formation of HCN.	Oxadiazoles	68-78	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	122-125
34275792-5	2021	The hydrazides were cyclized with CS2 in the presence of KOH to yield corresponding oxadiazoles (4a-f).	Oxadiazoles	84-95	chorionic somatomammotropin hormone 2	Homo sapiens	34-37
34089945-3	2021	Herein, 4-benzyl-2-benzylthio-5-methyl-1H-imidazole (2a) and 4-benzyl-5-methyl-2-((2,6-difluorobenzyl)thio)-1H-imidazole (2d) from a group of thirty imidazole-bearing compounds showed greater STAT3 inhibition than their lead compounds VS1 and the oxadiazole derivative MD77.	Oxadiazoles	247-257	signal transducer and activator of transcription 3	Homo sapiens	192-197
34251799-1	2021	A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer"s disease.	Oxadiazoles	12-22	5-hydroxytryptamine receptor 4	Homo sapiens	69-99
34251799-1	2021	A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer"s disease.	Oxadiazoles	12-22	5-hydroxytryptamine receptor 4	Homo sapiens	101-107
34602444-0	2021	In-vitro cytotoxic evaluation of newly designed ciprofloxacin-oxadiazole hybrids against human liver tumor cell line (Huh7).	Oxadiazoles	62-72	MIR7-3 host gene	Homo sapiens	118-122
35189320-1	2022	A series of novel spirocyclic DGAT1 inhibitors containing the oxadiazole motif were designed and synthesized for biological evaluation.	Oxadiazoles	62-72	diacylglycerol O-acyltransferase 1	Mus musculus	30-35
35455397-11	2022	Many oxadiazoles showed lower IC50 values against AChE than established drug rivastigmine.	Oxadiazoles	5-16	acetylcholinesterase (Cartwright blood group)	Homo sapiens	50-54
33494672-6	2021	Results and Conclusion: It was observed that structures of the GSK-3 inhibitors comprised of benzopyridine, benzthiazole, pyrazole, pyrazine, dioxolo-benzoxazin, oxadiazole, benzimidazole in the skeletal with cyclopropylamide, phenyl carbamothioate, 3-[(propan-2-yl)oxy]propan-1-amine in side chain.	Oxadiazoles	162-172	glycogen synthase kinase 3 beta	Mus musculus	63-68
1179029-7	1975	The in vitro protection of trypsin-induced hydrolysis of bovine serum albumin, unlike antiinflammatory activity, was greater with oxadiazoles (30-90%) than the precursor thiosemicarbazides (4-50%) at a final concentration of 1 mM.	Oxadiazoles	130-141	albumin	Rattus norvegicus	64-77
35163965-0	2022	Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase.	Oxadiazoles	29-39	poly(ADP-ribose) polymerase 1	Homo sapiens	68-95
35163965-2	2022	Herein, oxadiazole based ligands that are predicted to target PARP-1 have been synthesized and screened for the loss of cell viability in mammary carcinoma cells, wherein seven compounds were observed to possess significant IC50 values in the range of 1.4 to 25 microM.	Oxadiazoles	8-18	poly(ADP-ribose) polymerase 1	Homo sapiens	62-68
35163965-7	2022	Finally, in silico analysis demonstrated binding of compound 5s towardsthe catalytic site of PARP-1, indicating that these novel oxadiazoles synthesized herein may serve as exemplars for the development of new therapeutics in cancer.	Oxadiazoles	129-140	poly(ADP-ribose) polymerase 1	Homo sapiens	93-99
33859800-4	2021	We describe the development of a novel class of oxadiazole KNa1.1 inhibitors, leading to the discovery of compound 31 that reduced seizures and interictal spikes in a mouse model of KCNT1 GoF.	Oxadiazoles	48-58	potassium channel, subfamily T, member 1	Mus musculus	182-187
32854311-1	2020	Analgesic and anti-inflammatory properties mediated by the kappa opioid receptor (KOR) have been reported for oxadiazole imidazodiazepines.	Oxadiazoles	110-120	opioid receptor kappa 1	Homo sapiens	59-80
33139114-11	2021	Ataluren, an oxadiazole compound that promotes read-through and expression of dystrophin in patients with Duchenne muscular dystrophy, bears some structural similarity to SRI-22819.	Oxadiazoles	13-23	dystrophin	Homo sapiens	78-88
33360082-3	2021	Aiming at the elucidation of MAO-B inhibitors with 1,3,4-oxadiazole scaffolds, we make a comprehensive update on the new and old chemical methods employed for the synthesis of the unsymmetrical oxadiazole derivatives that lead to high yield compounds.	Oxadiazoles	57-67	monoamine oxidase B	Homo sapiens	29-34
33360082-4	2021	We summarize a state of the selective MAO-B inhibitors with oxadiazole scaffold, describing the results, structures, structure-activity relationships (SARs) and medicinal chemistry strategies over the years.	Oxadiazoles	60-70	monoamine oxidase B	Homo sapiens	38-43
33360082-5	2021	The analysis of the recent papers would facilitate tracking the increasing number of oxadiazole derivatives as new chemical spaces with MAO-B inhibitory potential designed to ensure the safe use of the compounds and elimination of the unwanted drug-drug interactions.	Oxadiazoles	85-95	monoamine oxidase B	Homo sapiens	136-141
33256166-0	2020	Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.	Oxadiazoles	50-60	BCL2 apoptosis regulator	Homo sapiens	104-109
32854311-1	2020	Analgesic and anti-inflammatory properties mediated by the kappa opioid receptor (KOR) have been reported for oxadiazole imidazodiazepines.	Oxadiazoles	110-120	opioid receptor kappa 1	Homo sapiens	82-85
31945272-0	2020	From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.	Oxadiazoles	5-15	hypocretin neuropeptide precursor	Canis lupus familiaris	66-72
32325339-0	2020	Exploiting oxadiazole-sulfonamide hybrids as new structural leads to combat diabetic complications via aldose reductase inhibition.	Oxadiazoles	11-21	aldo-keto reductase family 1 member B	Homo sapiens	103-119
32451633-2	2020	The comparative study of optoelectronic properties indicates that thiadiazole with pyridine units containing molecules (M6b) exhibit lower energy of highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energy levels than those of oxadiazole and pyridine containing units (M6b).	Oxadiazoles	266-276	glycoprotein M6B	Homo sapiens	120-123
32631535-0	2020	Exploring the newer oxadiazoles as real inhibitors of human SIRT2 in hepatocellular cancer cells.	Oxadiazoles	20-31	sirtuin 2	Homo sapiens	60-65
32027778-5	2020	Several molecules containing a S-Et- or a S-Me-Itc moiety and mainly belonging to the dipeptide-like and 1,2,4-oxadiazole series were shown to inhibit nNOS and iNOS with IC50 in the 1-50 muM range.	Oxadiazoles	105-121	nitric oxide synthase 1	Rattus norvegicus	151-155
32027778-5	2020	Several molecules containing a S-Et- or a S-Me-Itc moiety and mainly belonging to the dipeptide-like and 1,2,4-oxadiazole series were shown to inhibit nNOS and iNOS with IC50 in the 1-50 muM range.	Oxadiazoles	105-121	nitric oxide synthase 2	Rattus norvegicus	160-164
31684051-0	2019	Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy.	Oxadiazoles	15-25	signal transducer and activator of transcription 3	Homo sapiens	74-79
31757525-0	2020	Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.	Oxadiazoles	86-110	AXL receptor tyrosine kinase	Homo sapiens	51-54
31195948-1	2020	BACKGROUND: In the recent past, we had synthesized and reported different derivatives of oxadiazoles as potential alpha-glucosidase inhibitors.	Oxadiazoles	89-100	sucrase-isomaltase	Homo sapiens	114-131
31622615-3	2020	Ursolic acid hydrazide provided access to oxadiazoles attached directly to C-17 of the ursane core, but synthesis of structurally related 3-mercapto-1,2,4-triazoles was not possible in this way due to steric hindrance of the triterpenoid.	Oxadiazoles	42-53	cytokine like 1	Homo sapiens	75-79
31539778-0	2019	New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.	Oxadiazoles	4-15	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	31-36
31539778-0	2019	New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.	Oxadiazoles	4-15	epidermal growth factor receptor	Homo sapiens	41-45
31999451-3	2020	The representative compound 8u bound effectively to IDO1, with greater inhibitory activity relative to the commercial IDO1 inhibitor 4-amino-N-(3-chloro-4-fluorophenyl)-N"-hydroxy-1, 2, 5-oxadiazole-3-carboximidamide (IDO5L) in addition to efficient suppression of nuclear translocation of STAT3.	Oxadiazoles	186-216	indoleamine 2,3-dioxygenase 1	Homo sapiens	52-56
31865813-5	2020	The recent invention of oxadiazole-based ligands by pharmaceutical companies may provide a new opportunity to optimize the druglike properties of HDAC6 inhibitors for the treatment of neurodegenerative diseases.	Oxadiazoles	24-34	histone deacetylase 6	Homo sapiens	146-151
31589148-6	2019	Two L5 ligands are bound to two Ag1 centres through two oxadiazole N and two pyridyl N atoms to form a macrocycle.	Oxadiazoles	56-68	NBPF member 10	Homo sapiens	32-35
31589148-7	2019	The other two oxadiazole N atoms coordinate to the two Ag2 centres of the Ag2(O2CCF3)4 dimer.	Oxadiazoles	14-24	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	55-58
31589148-7	2019	The other two oxadiazole N atoms coordinate to the two Ag2 centres of the Ag2(O2CCF3)4 dimer.	Oxadiazoles	14-24	anterior gradient 2, protein disulphide isomerase family member	Homo sapiens	74-77
31288965-0	2019	Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.	Oxadiazoles	16-26	G protein-coupled receptor 119	Rattus norvegicus	89-95
31196753-0	2019	Synthesis of oxadiazole-coupled-thiadiazole derivatives as a potent beta-glucuronidase inhibitors and their molecular docking study.	Oxadiazoles	13-23	glucuronidase beta	Homo sapiens	68-86
31196753-1	2019	A new series of oxadiazole with thiadiazole moiety (6-27) were synthesized, characterized by different spectroscopic techniques and evaluated for beta-glucuronidase inhibitory potential.	Oxadiazoles	16-26	glucuronidase beta	Homo sapiens	146-164
31187977-3	2019	In this contribution, a novel BF2-containing TADF molecule of BFOXD, which contains two acceptor fragments of oxadiazole (OXD) and BF2 and one donor unit of 9,9-dimethylacridine, was synthesized and characterized.	Oxadiazoles	110-120	forkhead box G1	Homo sapiens	30-33
29803079-0	2018	Synthesis, SAR elucidations and molecular docking study of newly designed isatin based oxadiazole analogs as potent inhibitors of thymidine phosphorylase.	Oxadiazoles	87-97	sarcosine dehydrogenase	Homo sapiens	11-14
31066976-0	2019	Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.	Oxadiazoles	0-10	hypocretin neuropeptide precursor	Rattus norvegicus	31-37
31003424-0	2019	Synthesis of Chromen-4-One-Oxadiazole Substituted Analogs as Potent beta-Glucuronidase Inhibitors.	Oxadiazoles	27-37	glucuronidase beta	Homo sapiens	68-86
31003424-1	2019	Chromen-4-one substituted oxadiazole analogs 1-19 have been synthesized, characterized and evaluated for beta-glucuronidase inhibition.	Oxadiazoles	26-36	glucuronidase beta	Homo sapiens	105-123
30792038-1	2019	Oxadiazole replacement of an amide linkage in an RARalpha agonist template 1, followed by lead optimisation, has produced a highly potent and selective RARbeta agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (10) with good oral bioavailability in the rat and dog.	Oxadiazoles	0-10	retinoic acid receptor, alpha	Rattus norvegicus	49-57
30792038-1	2019	Oxadiazole replacement of an amide linkage in an RARalpha agonist template 1, followed by lead optimisation, has produced a highly potent and selective RARbeta agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (10) with good oral bioavailability in the rat and dog.	Oxadiazoles	0-10	retinoic acid receptor, alpha	Rattus norvegicus	152-159
30599411-5	2019	In this regard we have synthesized benzothiazole based oxadiazole in search of potent anti-diabetic agent as alpha-glucosidase Inhibitors.	Oxadiazoles	55-65	sucrase-isomaltase	Homo sapiens	109-126
30599411-6	2019	Benzothiazole based oxadiazole derivatives 1-23 have been synthesized, characterized by 1HNMR, 13CNMR, and MS and evaluated for alpha-glucosidase Inhibition.	Oxadiazoles	20-30	sucrase-isomaltase	Homo sapiens	128-145
30857263-4	2019	Twenty-two (1-22) analogs of indole based oxadiazole were synthesized and screened for their inhibitory potential against beta-glucuronidase.	Oxadiazoles	42-52	glucuronidase beta	Homo sapiens	122-140
30591450-2	2019	The aim of this study was to explore the SAR of newly-synthesized oxadiazole derivatives and identify their molecular targets.	Oxadiazoles	66-76	sarcosine dehydrogenase	Homo sapiens	41-44
30280671-0	2019	3D-QSAR and Molecular Docking Studies on Oxadiazole Substituted Benzimidazole Derivatives: Validation of Experimental Inhibitory Potencies Towards COX-2.	Oxadiazoles	41-51	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	147-152
30268973-0	2019	Identification and Structure-Activity Relationship (SAR) of potent and selective oxadiazole-based agonists of sphingosine-1-phosphate receptor (S1P1).	Oxadiazoles	81-91	sphingosine-1-phosphate receptor 1	Homo sapiens	144-148
30268973-2	2019	In this paper we described a series of oxadiazole-based S1P1 direct-acting agonists disubstituted on terminal benzene ring, with high potency for S1P1 receptor and favorable selectivity against S1P3 receptor.	Oxadiazoles	39-49	sphingosine-1-phosphate receptor 1	Homo sapiens	56-60
30268973-2	2019	In this paper we described a series of oxadiazole-based S1P1 direct-acting agonists disubstituted on terminal benzene ring, with high potency for S1P1 receptor and favorable selectivity against S1P3 receptor.	Oxadiazoles	39-49	sphingosine-1-phosphate receptor 1	Homo sapiens	146-150
30996787-0	2019	Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists.	Oxadiazoles	25-35	nuclear receptor subfamily 1 group H member 4	Homo sapiens	101-104
30192504-3	2018	The oxadiazole compounds doped in hosts (mCP and PPT) emitted from 435 to 474 nm with photoluminescence quantum yields ranging from 14-55%.	Oxadiazoles	4-14	CD46 antigen, complement regulatory protein	Mus musculus	41-44
30192504-3	2018	The oxadiazole compounds doped in hosts (mCP and PPT) emitted from 435 to 474 nm with photoluminescence quantum yields ranging from 14-55%.	Oxadiazoles	4-14	tachykinin precursor 1	Homo sapiens	49-52
30568762-5	2018	Furthermore, docking of 6e/6h into the ATR structure active site revealed that the N1 and N8 atoms in the naphthyridine ring and the hybrid atom in the oxadiazole ring are involved in hydrogen bonding with Val170, Glu168 and Tyr155.	Oxadiazoles	152-162	serine/threonine-protein kinase ATR	Cricetulus griseus	39-42
28067996-1	2017	A new series of oxadiazoles were designed to act as inhibitors of the anti-apoptotic Bcl-2 protein.	Oxadiazoles	16-27	BCL2 apoptosis regulator	Homo sapiens	85-90
29223804-0	2018	Oxindole based oxadiazole hybrid analogs: Novel alpha-glucosidase inhibitors.	Oxadiazoles	15-25	sucrase-isomaltase	Homo sapiens	48-65
29223804-3	2018	Keeping in view the greater importance of alpha-glucosidase inhibitors here in this study we are presenting oxindole based oxadiazoles hybrid analogs (1-20) synthesis, characterized by different spectroscopic techniques including 1H NMR and EI-MS and their alpha-glucosidase inhibitory activity.	Oxadiazoles	123-134	sucrase-isomaltase	Homo sapiens	42-59
29223804-3	2018	Keeping in view the greater importance of alpha-glucosidase inhibitors here in this study we are presenting oxindole based oxadiazoles hybrid analogs (1-20) synthesis, characterized by different spectroscopic techniques including 1H NMR and EI-MS and their alpha-glucosidase inhibitory activity.	Oxadiazoles	123-134	sucrase-isomaltase	Homo sapiens	257-274
29960729-0	2018	Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3R ligands.	Oxadiazoles	54-64	histamine receptor H3	Homo sapiens	95-98
29960729-3	2018	This prompted us to design and synthesize azole-based H3R ligands, i.e. having oxadiazole- or thiazole-based core structures.	Oxadiazoles	79-89	histamine receptor H3	Homo sapiens	54-57
29966916-0	2018	Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.	Oxadiazoles	72-82	thymoma viral proto-oncogene 1	Mus musculus	120-123
29966916-0	2018	Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.	Oxadiazoles	72-82	PTK2 protein tyrosine kinase 2	Mus musculus	128-131
29864929-0	2018	Synthesis and amelioration of inflammatory paw edema by novel benzophenone appended oxadiazole derivatives by exhibiting cyclooxygenase-2 antagonist activity.	Oxadiazoles	84-94	prostaglandin-endoperoxide synthase 2	Homo sapiens	121-137
28677624-0	2017	Synthesis and Evaluation of New Oxadiazole, Thiadiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9.	Oxadiazoles	32-42	matrix metallopeptidase 9	Mus musculus	123-128
27928588-3	2017	In this study, the binding modes and inhibition mechanisms of the new oxadiazole-based amide inhibitors of the human soluble epoxide hydrolase were investigated by molecular docking and molecular dynamics (MD) simulation followed by the MM-GBSA method to calculate the binding free energy of each inhibitor to sEH.	Oxadiazoles	70-80	epoxide hydrolase 2	Homo sapiens	117-142
27928588-3	2017	In this study, the binding modes and inhibition mechanisms of the new oxadiazole-based amide inhibitors of the human soluble epoxide hydrolase were investigated by molecular docking and molecular dynamics (MD) simulation followed by the MM-GBSA method to calculate the binding free energy of each inhibitor to sEH.	Oxadiazoles	70-80	epoxide hydrolase 2	Homo sapiens	310-313
28067996-3	2017	Further study of the structure-activity relationship of the most active compound of the first series, compound 1, led to the discovery of a novel oxadiazole analogue, compound 16j, that was a more potent small-molecule inhibitor of Bcl-2.	Oxadiazoles	146-156	BCL2 apoptosis regulator	Homo sapiens	232-237
29050220-6	2017	With the aid of computer modeling for screening of chemicals targeting activation function 2 (AF-2) of AR, we identified oxadiazole derivatives as good candidates and subsequently generated a small library of these compounds.	Oxadiazoles	121-131	androgen receptor	Homo sapiens	103-105
27544072-1	2016	In continuation of our previous efforts directed towards the development of potent and selective inhibitors of aldose reductase (ALR2), and to control the diabetes mellitus (DM), a chronic metabolic disease, we synthesized novel coumarin-thiazole 6(a-o) and coumarin-oxadiazole 11(a-h) hybrids and screened for their inhibitory activity against aldose reductase (ALR2), for the selectivity against aldehyde reductase (ALR1).	Oxadiazoles	267-277	aldo-keto reductase family 1 member B	Homo sapiens	129-133
27544072-9	2016	Hence, the results of this study revealed that coumarinyl thiazole and oxadiazole derivatives could act as potential ALR1/ALR2 inhibitors.	Oxadiazoles	71-81	aldo-keto reductase family 1 member B	Homo sapiens	122-126
28160943-0	2017	Synthesis and in silico studies of novel sulfonamides having oxadiazole ring: As beta-glucuronidase inhibitors.	Oxadiazoles	61-71	glucuronidase beta	Homo sapiens	81-99
27923497-6	2017	Molecular docking study showed that morpholine and oxadiazole rings linked to the benzimidazole nucleus play an important role in binding with the COX-2.	Oxadiazoles	51-61	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	147-152
27987485-0	2017	Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.	Oxadiazoles	78-88	epidermal growth factor receptor	Homo sapiens	110-114
27987485-0	2017	Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.	Oxadiazoles	78-88	erb-b2 receptor tyrosine kinase 2	Homo sapiens	119-124
27987485-1	2017	The synthesis of benzimidazole linked oxadiazole derivatives designed as potential EGFR and erbB2 receptor inhibitors with anticancer and apoptotic activity were studied.	Oxadiazoles	38-48	epidermal growth factor receptor	Homo sapiens	83-87
27987485-1	2017	The synthesis of benzimidazole linked oxadiazole derivatives designed as potential EGFR and erbB2 receptor inhibitors with anticancer and apoptotic activity were studied.	Oxadiazoles	38-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	92-97